Regeneron Pharmaceuticals, Inc. Financials

Market Capitalization $59.14 Billion as of July 1, 2025

Valuations Metrics as of Jul. 4, 2025

Trailing PE	13.93
Forward PE	12.09
Price to Sales TTM	$4.20
Price to Book MRQ	$1.97
Enterprise to Revenue	3.54
Enterprise to EBITDA	11.15

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	31.94%
Operating Margin	19.94%
Return on Assets TTM	6.91%
Return on Equity TTM	15.96%

Income Statement

Revenue TTM	$14,085,699,584
Revenue per Share TTM	$130.88
Quarterly Revenue Growth	-3.70%
Gross Profit TTM	$6,873,699,840
EBITDA	$5,074,600,000
Net Income to Common TTM	$4,499,299,840
Diluted EPS TTM	$39.33
Quarterly Earnings Growth YoY	12.00%

Balance Sheet

Total Cash MRQ	$8,349,400,064
Total Cash per Share MRQ	$79.02
Total Debt MRQ	$
Total Debt to Equity MRQ	9.20
Current Ratio MRQ	4.93
Book Value per Share MRQ	$277.50

Cash Flow

Operating Cash Flow TTM	$3,953,100,032
Levered Free Cash Flow TTM	$2,082,887,552

REGN Stock Info as of Jul. 4, 2025

Stock Statistics

Shares Outstanding	109,617,146
Float Shares	99,889,821
Avg 10 Volume	1,139,160
Avg 30 Volume	None
Shares Short	2,031,432
Short Ratio	1.35
Short % of Shares	1.98%
% Held by Insiders	1.89%
% Held by Institutions	91.99%

Stock Price Summary

Beta	0.31
Fifty Two Week Low	$476.49
Fifty Two Week High	$1211.20
Fifty Two Week Change	-88.95%
Day 50 MA	$553.01
Day 200 MA	$719.28

Dividends and Splits

Forward Annual Dividend Rate	$3.52
Forward Annual Dividend Yield	0.64%
Trailing Annual Dividend Rate	$1.76
Trailing Annual Dividend Yield	0.32%
Payout Ratio	2.24%
Dividend Date	2025-06-06
Ex Dividend Date	2025-05-20
Last Split Factor
Last Split Date